Современные представления о терапии предменструального синдрома
https://doi.org/10.33667/2078-5631-2019-3-25(400)-18-23
Аннотация
Предменструальный синдром (ПМС) — распространенное заболевание, связанное с серьезным снижением качества жизни женщины, нарушением привычной жизнедеятельности и работоспособности. Этиология ПМС и предменструального дисфорического расстройства (ПМДР) до сих пор не установлена, но совершенно очевидно, что их развитие связано с колебанием уровня гормонов в пределах овуляторного менструального цикла и нарушением баланса нейрогормонов в центральной нервной системе (ЦНС). В связи с этими представлениями в терапии ПМС используют два основных направления: подавление гормональных флуктуаций и воздействие на ЦНС. Среди большого числа средств, заявленных для терапии ПМС и ПМДР, особого внимания заслуживает так называемая альтернативная терапия, в рамках которой несколько методов имеют достойную доказательную базу положительного действия.
Об авторе
И. В. Кузнецова
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет) Минздрава России
Россия
Россия
д. м. н., проф. кафедры акушерства и гинекологии № 1, Институт клинической медицины
г. Москва
Список литературы
1. Hofmeister S, Bodden S. Premenstrual syndrome and premenstrual dysphoric disorder. Am Fam Physician. 2016; 94: 236–240.
2. Gynaecologists RCOG. Management of premenstrual syndrome. Green-top Guideline No. 48. BJOG. 2017; 124: e73–105.
3. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018; 218 (1): 68–74.
4. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010; 3: 485–494.
5. Steiner M, Peer M, Palova E, Freeman E, Macdougall M, Soares CN. The Premenstrual Symptoms Screening Tool revised for adolescents (PSST-A): Prevalence of severe PMS and premenstrual dysphoric disorder in adolescents. Arch Womens Ment Health. 2011; 14: 77–81.
6. Dueñas JL, Lete I, Bermejo R, Arbat A, et al. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a representative cohort of Spanish women of fertile age. Eur J Obstet Gynecol Reprod Biol. 2011; 156: 72–77.
7. Nevatte T, O’Brien PMS, Bäckström T, et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health. 2013; 16 (4): 279–291.
8. Matsumoto T, Asakura H, Hayashi T (2013) Biopsychosocial aspects of premenstrual syndrome and premenstrual dysphoric disorder. Gynecol Endocrinol 29 (1), 67–73.
9. Hartlage SA, Freels A, Gotman N, Yonkers KA. Criteria for premenstrual dysphoric disorder (PMDD): secondary analyses of relevant data sets. Arch Gen Psychiatry. 2012; 69 (3): 300–305.
10. Bäckström T, Haage D, Löfgren M, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons. Neuroscience. 2011; 191: 46–54.
11. Andréen L, Nyberg S, Turkmen S, van Wingen G, Fernández G, Bäckström T. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators. Psychoneuroendocrinology. 2009; 34: 1121–1132.
12. Segebladh B, Borgström A, Nyberg S, Bixo M, Sundström-Poromaa I. Evaluation of different add-back estradiol and progesterone treatments to gonadotropin-releasing hormone agonist treatment in patients with premenstrual dysphoric disorder. Am J Obstet Gynecol. 2009; 201: 139, e1–e8.
13. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009; 56: 141–148.
14. Houghton SC, Bertone-Johnson ER. Macronutrients and premenstrual syndrome. In: Advances in Medicine and Biology. [Berhardt LV, editor]. NOVA Science Publishers, Inc. 2015.
15. Brinkman MT, Baglietto L, Krishnan K, et al. Consumption of animal products, their nutrient components and postmenopausal circulating steroid hormone concentrations. Eur J Clin Nutr. 2010; 64 (2): 176–183.
16. Houghton SC, Manson JE, Whitcomb BW, et al. Intake of dietary fat and fat subtypes and risk of premenstrual syndrome in the Nurses’ Health Study II. Br J Nutr. 2017; 118 (10): 849–857.
17. Houghton SC, Manson JE, Whitcomb BW et al. Carbohydrate and fiber intake and the risk of premenstrual syndrome. Eur J Clin Nutr. 2018; 72 (6): 861–870.
18. Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Dietary B vitamin intake and incident premenstrual syndrome. Am J Clin Nutr. 2011; 93 (5): 1080–1086.
19. Chocano-Bedoya PO, Manson JE, Hankinson SE, et al. Intake of selected minerals and risk of premenstrual syndrome. Am J Epidemiol. 2013; 177 (10): 1118–1127.
20. Parry BL, Meliska CJ, Sorenson DL. Increased sensitivity to light-induced melatonin suppression in premenstrual dysphoric disorder. Chronobiol Int. 2010; 27 (7): 1438–1453.
21. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD 006586.
22. Freeman EW, Halbreich U, Grubb GS, Rapkin AJ, Skouby SO, Smith L, Mirkin S, Constantine GD. An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg / ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. Contraception. 2012; 85: 437–445.
23. Brown J, O’Brien PMS, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD 001396.
24. Freeman EW, Sammel MD, Lin H, Rickels K, Sondheimer J. Clinical subtypes of premenstrual syndrome and responses to sertraline treatment. Obstet Gynecol. 2011; 118: 1293–1300.
25. Moret C, Isaac M, Briley M. Problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharm. 2009; 23: 967–974.
26. Studd J. A guide to the treatment of depression women by hormones. Climacteric. 2011; 14: 637–642.
27. Pincus SM, Alam S, Rubinow DR, Bhuvaneswar CG, Schmidt PJ. Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res. 2011; 45: 386–394.
28. Busse JW, Montori VM, Krasnik C, Patelis-Siotis I, Guyatt GH. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2009; 78: 6–15.
29. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive–behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Women Ment Health. 2009; 12: 85–96.
30. Daley A. Exercise and premenstrual symptomatology: a comprehensive review. J Women Health (Larchmt). 2009; 18: 895–899.
31. Shechter A, Boivin DB. Sleep, hormones, and circadian rhythms throughout the menstrual cycle in healthy women and women with premenstrual dysphoric disorder. Int J Endocrinol. 2010; 2010: 259345.
32. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol. 2009; 16: 407–429.
33. Khajehei M, Abdali K, Parsanezhad ME, Tabatabaee HR. Effect of treatment with dydrogesterone or calcium plus vitamin D on the severity of premenstrual syndrome. Int J Gynaecol Obstet. 2009; 105: 158–161.
34. Rocha Filho EA, Lima JC, Pinho Neto JS, Montarroyos U. Essential fatty acids for premenstrual syndrome and their effect on prolactin and total cholesterol levels: a randomized, double blind, placebo-controlled study. Reprod Health. 2011; 8: 2.
35. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol. 2011; 32: 42–51.
36. Торшин И. Ю., Громова О. А., Лиманова О. А. Систематический анализ состава и механизмов молекулярного воздействия стандартизированных экстрактов Vitex Agnus-castus. Трудный пациент. 2015; 1–2: 19–29.
37. Van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med 2013; 79 (7): 562–575.
38. Lanc C, Taylor-Swansson L, Westfall R. Herbal fertility treatments used in North America from colonial times to 1900, and their potential for improving the success rate of assisted reproductive technology. Reprod Biomed Soc Online. 2018; 5: 60–81.
39. Chattopadhyay P, Hazarika S, Dhiman S, et al. Vitex negundo inhibits cyclooxygenase-2 inflammatory cytokine-mediate inflammation on carrageenan-induced rat hind paw edema. Pharmacognosy Res. 2012; 4 (3): 134–137.
40. Choudhary MI, Jalil S, Nawaz SA, et al. Antiinflammatory and lipoxygenase inhibitory compounds from Vitex agnus-castus. Phytoter Res. 2009; 23 (9): 1336–1339.
41. Bae H, Kim Y, Lee E, et al. Vitex rofundifolia L. prevented airway eosinophilic inflammation and airway remodeling in an ovalbumin-induced asthma mouse model. Int Immunol. 2013; 25 (3): 197–205.
42. Park SE, Sapkota K, Choi JH, et al. Rutin from Dendropanax morbifera Leveille protects human dopaminergic cells against rotenone induced cell injury through inhibiting JNK and p38 MAPK signaling. Neurochem Res. 2014; 39 (4): 707–718.
43. Al-Dhabi NA, Arasu MV, Park CH, Park SU. Recent studies on rosmarinic acid and its biological and pharmacological activities. EXCLI J. 2014; 13: 1192–1195.
44. Shen W, Qi R, Zhang J, et al. Chlorogenic acid inhibits LPS-induced microglial activation and improves survival of dopaminergic neurons. Brain Res Bull. 2012; 88 (5): 487–494.
45. He Z, Chen R, Zhou Y, et al. Treatment for premenstrual syndrome with Vitex agnus castus: A prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009; 63 (1): 99–103.
46. Jang SH, Kim DI, Choi MS. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome / premenstrual dysphoric disorder: systematic review. BMC Complement Altern Med. 2014: 11.
47. Ma L, Lin S, Chen R, Zhang Y, Chen F, Wang X. Evaluating therapeutic effect in symptoms of moderate-to-severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Aust N Z J Obstet Gynaecol. 2010; 50 (2): 189–193.
48. Ma L, Lin S, Chen R, Wang X. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in Chinese women. Gynaecol Endocrinol. 2010; 26 (8): 612–616.
49. Weisz G, Knaapen L. Diagnosing and treating premenstrual syndrome in five western nations. Soc Sci Med. 2009; 1498–1505.
50. Doll M. The premenstrual syndrome: effectiveness of Vitex agnus castus. Med Monatsschr Pharm. 2009; 32 (5): 186–191.
51. Zamani M, Neghab N, Torabian S. Therapeutic effect of Vitex agnus castus in patients with premenstrual syndrome. Acta Med Iran. 2012; 50 (2): 101–106.
52. Ambrosini A, Di Lorenzo C, Coppola G, Pierelli F. Use of Vitex agnus-castus in migrainous women with premenstrual syndrome: an open-label clinical observation. Acta Neurol Psychiatr Belg. 2013; 113 (1): 25–29.
53. Momoeda M, Sasaki H, Tagashira E, Ogishima M, Takano Y, Ochiai K. Efficacy and safety of Vitex agnus-castus extract of premenstrual syndrome in Japanese patients: a prospective, open label study. Adv Ther. 2014; 31 (3): 362–373.
54. van Die MD, Bone KM, Burger HG, Reece JE, Teede HJ. Effects of a combination of Hypeicum perforatum and Vitex agnus-castus on PMS-like symptoms in late-perimenopausal women: findings from subpopulation analysis. J Altern Complement Med. 2009; 15 (9): 1045–1048.
Рецензия
Для цитирования:
Кузнецова И.В. Современные представления о терапии предменструального синдрома. Медицинский алфавит. 2019;3(25):18-23. https://doi.org/10.33667/2078-5631-2019-3-25(400)-18-23
For citation:
Kuznetsova I.V. Modern views on treatment of premenstrual syndrome. Medical alphabet. 2019;3(25):18-23. (In Russ.) https://doi.org/10.33667/2078-5631-2019-3-25(400)-18-23
Просмотров:
870
Послать статью по эл. почте 